Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Double-Blind, Double-Dummy Study to Explore the Long-Term Safety and Efficacy of TEV-48125 for the Prevention of Cluster Headache

Trial Profile

A Multicenter, Double-Blind, Double-Dummy Study to Explore the Long-Term Safety and Efficacy of TEV-48125 for the Prevention of Cluster Headache

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 21 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fremanezumab (Primary)
  • Indications Cluster headache
  • Focus Adverse reactions
  • Acronyms ENFORCE
  • Sponsors Teva Branded Pharmaceutical Products R&D

Most Recent Events

  • 21 Jan 2022 This trial has been completed in Finland (Date of the global end of the trial : 11-Jun-2019), according to European Clinical Trials Database record.
  • 13 Mar 2020 This trial has been completed in Netherland (Global End Date: 23 Apr 2019), according to European Clinical Trials Database record.
  • 10 May 2019 This trial has been completed in Sweden, according to European Clinical Trials Database.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top